CN113832204A - Nmn的制备方法及含nmn的犬猫抗衰老保健品配方 - Google Patents
Nmn的制备方法及含nmn的犬猫抗衰老保健品配方 Download PDFInfo
- Publication number
- CN113832204A CN113832204A CN202111110078.5A CN202111110078A CN113832204A CN 113832204 A CN113832204 A CN 113832204A CN 202111110078 A CN202111110078 A CN 202111110078A CN 113832204 A CN113832204 A CN 113832204A
- Authority
- CN
- China
- Prior art keywords
- nmn
- parts
- bifidobacterium breve
- aging
- beta
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000282326 Felis catus Species 0.000 title claims abstract description 27
- 230000036541 health Effects 0.000 title claims abstract description 21
- 230000003712 anti-aging effect Effects 0.000 title claims abstract description 19
- 238000002360 preparation method Methods 0.000 title claims abstract description 9
- 241000282472 Canis lupus familiaris Species 0.000 claims abstract description 19
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 18
- 241000186012 Bifidobacterium breve Species 0.000 claims abstract description 17
- 238000000034 method Methods 0.000 claims abstract description 17
- 235000021323 fish oil Nutrition 0.000 claims abstract description 9
- 229960003080 taurine Drugs 0.000 claims abstract description 9
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims abstract description 8
- 229940067606 lecithin Drugs 0.000 claims abstract description 8
- 235000010445 lecithin Nutrition 0.000 claims abstract description 8
- 239000000787 lecithin Substances 0.000 claims abstract description 8
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims abstract description 6
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims abstract description 6
- 235000021283 resveratrol Nutrition 0.000 claims abstract description 6
- 229940016667 resveratrol Drugs 0.000 claims abstract description 6
- 108090000790 Enzymes Proteins 0.000 claims abstract description 3
- 102000004190 Enzymes Human genes 0.000 claims abstract description 3
- DAYLJWODMCOQEW-TURQNECASA-N NMN zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)([O-])=O)O2)O)=C1 DAYLJWODMCOQEW-TURQNECASA-N 0.000 claims abstract 21
- 239000000047 product Substances 0.000 claims description 26
- 239000007788 liquid Substances 0.000 claims description 15
- 102000015532 Nicotinamide phosphoribosyltransferase Human genes 0.000 claims description 8
- 108010064862 Nicotinamide phosphoribosyltransferase Proteins 0.000 claims description 8
- 238000000605 extraction Methods 0.000 claims description 8
- 239000002994 raw material Substances 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims description 6
- 230000003197 catalytic effect Effects 0.000 claims description 6
- 230000009089 cytolysis Effects 0.000 claims description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 4
- 239000000706 filtrate Substances 0.000 claims description 4
- 239000008103 glucose Substances 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- 239000001888 Peptone Substances 0.000 claims description 3
- 108010080698 Peptones Proteins 0.000 claims description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 3
- 238000011033 desalting Methods 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 229910052564 epsomite Inorganic materials 0.000 claims description 3
- 238000001704 evaporation Methods 0.000 claims description 3
- 230000008020 evaporation Effects 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 235000019253 formic acid Nutrition 0.000 claims description 3
- 239000001963 growth medium Substances 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- 238000005342 ion exchange Methods 0.000 claims description 3
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 claims description 3
- 229910000357 manganese(II) sulfate Inorganic materials 0.000 claims description 3
- 244000005700 microbiome Species 0.000 claims description 3
- 238000002414 normal-phase solid-phase extraction Methods 0.000 claims description 3
- 235000019319 peptone Nutrition 0.000 claims description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 3
- 229920000053 polysorbate 80 Polymers 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 238000001556 precipitation Methods 0.000 claims description 3
- 239000011347 resin Substances 0.000 claims description 3
- 229920005989 resin Polymers 0.000 claims description 3
- 239000001632 sodium acetate Substances 0.000 claims description 3
- 235000017281 sodium acetate Nutrition 0.000 claims description 3
- 239000006228 supernatant Substances 0.000 claims description 3
- 229910021654 trace metal Inorganic materials 0.000 claims description 3
- 238000000108 ultra-filtration Methods 0.000 claims description 3
- 229940035893 uracil Drugs 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 3
- 241000186000 Bifidobacterium Species 0.000 claims description 2
- 229910000396 dipotassium phosphate Inorganic materials 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 239000013612 plasmid Substances 0.000 claims description 2
- 239000007858 starting material Substances 0.000 claims description 2
- 241000282465 Canis Species 0.000 claims 1
- 241000282324 Felis Species 0.000 claims 1
- FZAQROFXYZPAKI-UHFFFAOYSA-N anthracene-2-sulfonyl chloride Chemical compound C1=CC=CC2=CC3=CC(S(=O)(=O)Cl)=CC=C3C=C21 FZAQROFXYZPAKI-UHFFFAOYSA-N 0.000 abstract description 95
- 230000032683 aging Effects 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 6
- 238000006555 catalytic reaction Methods 0.000 abstract description 2
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 2
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 230000005778 DNA damage Effects 0.000 abstract 1
- 231100000277 DNA damage Toxicity 0.000 abstract 1
- 208000026106 cerebrovascular disease Diseases 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- 230000037149 energy metabolism Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 24
- 229950006238 nadide Drugs 0.000 description 24
- 238000001514 detection method Methods 0.000 description 20
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 15
- 229910052698 phosphorus Inorganic materials 0.000 description 15
- 239000011574 phosphorus Substances 0.000 description 15
- 238000012360 testing method Methods 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 9
- JLEBZPBDRKPWTD-TURQNECASA-O N-ribosylnicotinamide Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=C1 JLEBZPBDRKPWTD-TURQNECASA-O 0.000 description 8
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 8
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000002243 precursor Substances 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- 238000001228 spectrum Methods 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 235000009200 high fat diet Nutrition 0.000 description 6
- 210000000593 adipose tissue white Anatomy 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 235000019197 fats Nutrition 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 235000019621 digestibility Nutrition 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 235000005152 nicotinamide Nutrition 0.000 description 4
- 239000011570 nicotinamide Substances 0.000 description 4
- 229960003966 nicotinamide Drugs 0.000 description 4
- 235000001968 nicotinic acid Nutrition 0.000 description 4
- 239000011664 nicotinic acid Substances 0.000 description 4
- 229960003512 nicotinic acid Drugs 0.000 description 4
- 210000002027 skeletal muscle Anatomy 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 241000607142 Salmonella Species 0.000 description 3
- 230000003187 abdominal effect Effects 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000002115 aflatoxin B1 Substances 0.000 description 3
- OQIQSTLJSLGHID-WNWIJWBNSA-N aflatoxin B1 Chemical compound C=1([C@@H]2C=CO[C@@H]2OC=1C=C(C1=2)OC)C=2OC(=O)C2=C1CCC2=O OQIQSTLJSLGHID-WNWIJWBNSA-N 0.000 description 3
- 229930020125 aflatoxin-B1 Natural products 0.000 description 3
- 229910052785 arsenic Inorganic materials 0.000 description 3
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 3
- 239000000306 component Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 235000021316 daily nutritional intake Nutrition 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000003648 hair appearance Effects 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 235000019750 Crude protein Nutrition 0.000 description 2
- XLYOFNOQVPJJNP-ZSJDYOACSA-N Heavy water Chemical compound [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 235000019784 crude fat Nutrition 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 229910001385 heavy metal Inorganic materials 0.000 description 2
- 230000003752 improving hair Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000004611 spectroscopical analysis Methods 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 238000000825 ultraviolet detection Methods 0.000 description 2
- 238000004679 31P NMR spectroscopy Methods 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 230000009084 cardiovascular function Effects 0.000 description 1
- 239000008358 core component Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000011133 lead Substances 0.000 description 1
- 230000007056 liver toxicity Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000001728 nano-filtration Methods 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
- C12P19/28—N-glycosides
- C12P19/30—Nucleotides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/105—Aliphatic or alicyclic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/142—Amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/153—Nucleic acids; Hydrolysis products or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/158—Fatty acids; Fats; Products containing oils or fats
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C07H1/06—Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/048—Pyridine radicals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Biochemistry (AREA)
- Animal Husbandry (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Birds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Fodder In General (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种NMN的制备方法及含NMN的犬猫抗衰老保健品配方。NMN(β‑烟酰胺单核苷酸)采用含NMN短双岐杆菌生物酶催化法制备,得到纯度99.97%的β‑NMN。一种含NMN的犬猫抗衰老保健品配方,包括60‑85份鱼油、1‑10份β‑NMN、0.05‑0.2份白藜芦醇、5‑20份牛磺酸和1‑15份卵磷脂。本发明能有效修复DNA损伤,延缓犬猫衰老,提高生命活力,增强能量代谢,缓解疲劳,对心脑血管疾病、经退行性病及老化退行性疾病等也具有较好的预防和修复作用。
Description
技术领域
本发明属于犬猫抗衰老保健品技术领域,特别是涉及NMN的制备方法及含NMN的犬猫抗衰老保健品配方。
背景技术
近现代以来,随着宠物食品质量的提升,宠物营养水平也随之提高,同时医疗水平也不断提升,使宠物年龄更加延长,近60年数据统计发现,宠物的平均年龄翻了2倍。进入21世纪以来,宠物保健品的科研资源投入不断增加,市面上出现各式各样的宠物保健产品,其中关于延长宠物寿命的保健较为热门。
随着宠物年龄的增长,例如宠物犬猫步入中年以后体内NAD+(中文名烟酰胺腺嘌呤二核苷酸,简称为辅酶Ⅰ)水平不断下降,导致线粒体的活性衰退,即出现衰老现象。改善犬猫体内NAD+活性能够有效地增强线粒体的功能,从来缓解衰老,所以补充NAD+是抗衰老的关键之一。补充NAD+的方式主要是补充NAD+的前体物质,目前研究报道发现NAD+有四种前体物质,NMN(β-烟酰胺单核苷酸)与其它的NAD+前体如烟酰胺核糖(NR)、烟酸(NA)和烟酰胺(NAM)在结构上相似,均含有吡啶环结构;但烟酸(NA)和烟酰胺(NAM)在应用方面存在一些缺点,如烟酰胺会引起恶心呕吐以及过敏的风险,而高剂量服用烟酰胺会引起肝脏毒性,四种NAD+前体物质中,NMN是补充效率最高的NAD+前体物质,NMN会被机体高效代谢,不会引起任何明显的有害影响。目前中国市场上NMN产品主要是人用级别的,在宠物市场上,还没有一款含NMN的抗衰老犬猫保健品。
发明内容
为了克服现有技术的不足,本发明的目的是提供一种NMN的制备方法及含NMN的犬猫抗衰老保健品配方。
一种NMN的制备方法,步骤如下:
1)微生物培养
含NMN短双岐杆菌培养基条件为:MRS培养,进行催化NMN的表达;所述的MRS含1%蛋白胨,2%葡萄糖,0.1%吐温80,0.2%K2HPO4,0.5%乙酸钠,0.2% 氢二铵,0.02%MgSO4·7H2O,0.005% MnSO4·4H2O,0.1%微量金属溶解液和0.0076%的尿嘧啶,外源添加催化酶烟酰胺磷酸核糖转移酶(nicotinamide phosphoribosyltransferase);
2)NMN培养滤液获取
含NMN的短双岐杆菌用转速2200g进行离心,分别收集每管细胞的上清液,将细胞进重悬浮,再利用超声细胞破碎器在冰浴上进行超声裂解,每次30秒,循环3次,超声进一步裂解之后再行超滤最终得到NMN料液;
3)NMN料液萃取
将含NMN料液与相同体积的质量百分比浓度4% 的NaHCO3混合,用于Bond ElutPBA树脂固相萃取;萃取液用3ml 2%的NaHCO3洗涤后,再用3ml 2%的甲酸进行洗脱,得到β-NMN萃取液;
4)NMN原料制备
用离子交换法进行对NMN萃取液进行除盐处理,然后用醇提水沉法进行脱色处理,脱完色后用蒸发溶剂法进行NMN液体的结晶,结晶样品加水溶解,用转速2200g进行离心过滤,最后对样品进行干燥后得到NMN原料。
所述的短双歧杆菌的编号为bifidobacterium breve K,双歧杆菌属,先准备短双岐杆菌感受态细胞,然后导入含有NMN活性序列的质粒到感受态的短双岐杆菌得到NMN短双岐杆菌。
所述的烟酰胺磷酸核糖转移酶为外源酶,添加量8g/L。
一种含NMN的犬猫抗衰老保健品配方,按质量份,包括60-85份鱼油、1-10份β-NMN、0.05-0.2份白藜芦醇、5-20份牛磺酸和1-15份卵磷脂。
所述的含NMN的犬猫抗衰老保健品配方,包括冻干、粉剂、胶囊或者液体的形态。
本发明有益效果:
该抗衰老配方制成的产品,有助于通过提升体内NAD+的水平来缓解犬猫的衰老状况,改善犬猫毛发粗糙的状态,此外,该配方产品还能改善犬猫易疲劳的状态,增加生命活力。其中,鱼油是载体,NMN为发挥作用的核心成分。添加白藜芦醇、牛磺酸等是为了让NMN能更持久的发挥作用,单一NMN成分的产品在服用一星期后效果就会显著下降,通过添加这些成分能够让NMN的作用时间延长到2个星期。
表1. 各成分功能
成分 | 功能 |
Β-烟酰胺单核苷酸(NMN) | NAD+的前提物质,通过增加NAD+的体内表达水平来改善线粒体活性以及修复损伤的DNA等,从而缓解动物衰老状况 |
鱼油 | 改善毛发,降低动物胆固醇水平 |
白藜芦醇 | 改善机体抗氧化水平,保护心血管功能 |
牛磺酸 | 增强犬猫尤其是猫的免疫力 |
卵磷脂 | 改善毛发,减少犬猫掉毛 |
附图说明
图1是NMN抗衰老保健品的实物图。
图2是NMN磷谱检测图。
图3是HPLC分析NMN的纯度。
图4是骨骼肌NAD+水平。
图5是白色脂肪组织(WAT)NAD+水平。
图6是肺部NAD+水平。
图7是不同组别猫平均日采食量。
具体实施方式
下面结合附图和实施例对本发明进一步说明。
实施例1、NMN提取以及指标检测
NMN的提取过程主要过程如下:
①微生物培养。含NMN短双岐杆菌培养基条件为:MRS培养(含1%蛋白胨,2%葡萄糖,0.1%吐温80,0.2%K2HPO4, 0.5%乙酸钠,0.2% 氢二铵,0.02%MgSO4·7H2O,0.005% MnSO4·4H2O,0.1%微量金属溶解液和0.0076%的尿嘧啶,外源添加催化酶烟酰胺磷酸核糖转移酶(nicotinamide phosphoribosyltransferase )进行催化NMN的催化表达。
②NMN培养滤液获取。含NMN的短双岐杆菌用转速2200g进行离心,分别收集每管细胞的上清液,将细胞进重悬浮,再利用超声细胞干扰器在冰上进行超声裂解,每次30秒,循环3次,超声进一步裂解之后再行超滤和纳滤最终得到NMN料液。
③NMN料液萃取。将含NMN的培养滤液(15 ml)与相同体积的4% NaHCO3混合,用于Bond Elut PBA树脂固相萃取。萃取液用3ml 2%的NaHCO3洗涤后,再用3ml 2%的甲酸进行洗脱,得到的萃取液用于HPLC分析。HPLC参数如下:柱型:Hypersil BDS C18,5u,200*4.6;流动相:10%乙腈和pH 6.0缓冲液(V/V) ,流速:1mL/min;检测:UV检测,254nm;柱温:25°C。 ④NMN原料制备。用离子交换法进行对NMN萃取液进行除盐处理,然后用醇提水沉法进行脱色处理,脱完色后用蒸发溶剂法进行NMN液体的结晶,结晶样品加水溶解,用转速2200g进行离心过滤,最后对样品进行干燥后得到NMN原料。
⑤含NMN的抗衰老保健产品制备。预混料按分量(1-10份NMN(β-NMN)、0.05-0.2份白藜芦醇、5-20份牛磺酸和1-15份卵磷脂)称取混合到60-85份鱼油中,最终成品制成软胶囊形态。NMN抗衰老保健品的实物图如图1所示。
⑥含NMN鱼油胶囊的检测。对NMN样品进行微量元素、营养指标、微生物以及重金属等指标检测,检测项目包括,粗蛋白、粗脂肪、粗纤维、水分、铅、砷、牛磺酸、EPA、DHA、DPA、β-烟酰胺单核苷酸(β-NMN)、卵磷脂、沙门氏菌、大肠杆菌、黄曲霉毒素B1。
表2.NMN犬猫保健品部分指标检测结果
检测指标 | 计量单位 | 检测结果 | 检测方法 |
粗蛋白 | % | 8.18 | GB/T 6432-2018 7.2 |
粗脂肪 | % | 85.2 | GB/T 6433-2006(A类) |
粗灰分 | % | 1.2 | GB/T 6438-2007 |
粗纤维 | % | 0.35 | GB/T 6434-2006 |
水分 | % | 0.34 | GB/T 6434-2006 |
牛磺酸 | mg/100g | 7.81*10^3 | GB 5009.169-2016第一法 |
EPA | g/100g | 41.6 | GB/T 21514-2008 |
DHA | g/100g | 22.1 | GB/T 21514-2008 |
DPA | g/100g | 3.22 | GB/T 21514-2008 |
β-烟酰胺单核苷酸(β-NMN) | mg/100g | 4.67*10^3 | GB/T 6434-2006 |
卵磷脂 | mg/100g | 6.25*10^3 | GB/T 35867-2018 |
砷 | ppm | 未检出 | GB/T 13079-2006 7 |
铅 | ppm | 未检出 | GB/T 13080-2018 7.1 |
大肠杆菌 | CFU/g | 未检出 | GB 4789.3-2016 第二法 |
沙门氏菌 | CFU/g | 未检出 | GB/T 6434-2006 |
黄曲霉毒素B1 | μg/kg | 未检出(定量限1.0) | GB/T 30955-2014 |
试验结果如下,样品的理化生化检测指标结果如表2所示,EPA,DHA和DPA总含量达66%,在添加量范围内,说明经过胶囊包装后,鱼油性状基本稳定,另外牛磺酸、卵磷脂、β-NMN都在添加量范围内。重金属指标方面,砷和铅均未检出,细菌毒素方面,大肠杆菌、沙门氏菌和黄曲霉素B1都低于检测限未检出,说明该产品的安全性较高。以上所有指标的检测方法都严格按照国标进行检测。
实施例2、NMN原料结构分析
①根据实施例1中获取的NMN原料,对NMN结构进行纯度检测,纯度检测使用高效液相色谱仪器进行检测HPLC参数如下:柱型:Hypersil BDS C18,5u,200*4.6;流动相:10%乙腈和pH 6.0缓冲液(V/V) ,流速:1mL/min;检测:UV检测,254nm;柱温:25°C。
②对NMN进行含磷化合物检测,采用磷谱检测方法,磷谱检方法数如下,仪器采用Burker AVANCE-300超导核磁共振仪,溶剂为D2O,重水毛细管锁场,样品浓度稀释到25%,以四甲基硅烷为内标,样品管径为5mm,同核去偶用综合频率发生器,频率为1Hz,测定含磷化合物的31P NMR值。
试验结果如下,核磁共振磷谱中,含磷化合物均会有信号出现,即出现化学位移,磷谱检测结果如图2所示,在化学位移0.00处出现了峰值,即含磷酸基团,其他化学位移均未出现化学位移,该检测结果与NMN结构本身含磷酸基团一致,无其他化学位移说明该NMN样品只含单一磷酸基团,纯度极高。另外,磷谱检测的目的还可以用来证明该原料不是烟酰胺核糖(NR),NR没有磷谱数据,NR也是NAD+的前体补充剂,结构与NMN类似,因此很多声称含NMN产品其实用NR来冒充NMN,而磷谱检测能较快也较准确地判断出是里面的有效成分否为NR。
在核磁共振磷谱的基础上,我们进行了下一步试验,通过HPLC分析NMN纯度发现,如图3所示,图谱中共出现两个峰,电信号强度分别是497毫吸光度单位(m AbsorbanceUnit,mAU)和1595697mAU,总电信号强度为1596194mAU,其中2号峰即2.534处峰的面积占总面积的99.97%,说明该样品中NMN纯度高达99.97%,该结果符合磷谱检测的预期,说明通过生物酶催化法提取的NMN纯度极高,几乎无副产物,相对纯度一般的NMN来说,高纯度NMN的安全性更高。
实施例3、腹腔注射NMN对小鼠体内NAD+水平的影响
小鼠在6个月龄时用高脂饮食(HFD)诱导的二型糖尿病(T2D)模型,将糖尿病定义为空腹血糖水平>120mg /dl小鼠的定义为T2D小鼠。小鼠分组如下:1、对照组,正常饲养的小鼠。2、HFD组,高脂饲喂的小鼠,3、HFD+NMN组,高脂饲喂后注射NMN。对于NMN治疗,采用腹腔内注射NMN,剂量为500 mg/kg体重/天,每4天注射1次,注射4次。注射结束后第4天(即试验开始的第20天)采集小鼠肺部、白色脂肪组织(WAT)、骨骼肌,采集后立即液氮中速冻,然后收集样品放入-20℃冰箱保存。使用HPLC仪器分析样品组织中的NAD+水平。
表3. 试验分组
组别 | 饲喂方式 | 注射方式 | 饲养周期 |
CON组 | 饲喂正常饲料 | 腹腔注射 | 20天 |
HFD组 | 饲喂高脂饲料 | 腹腔注射 | 20天 |
HFD+NMN组 | 饲喂高脂饲料 | 腹腔注射 | 20天 |
试验结果如下,相比于对照组,高脂饲喂的小鼠,肺部、WAT和骨骼肌的NAD+水平显著性下降,说明出现了一定的衰老现象,而腹腔注射了4次NMN之后,NAD+水平显著性上升,其中骨骼肌和肺部的NAD+水平高于CON组,说明体内的抗氧化能力得到了较大的提升,结果表明腹腔注射NMN能有效增加小鼠体内NAD+水平,如图4、图5和图6所示。
实施例4、饲喂含NMN抗衰老保健品对猫健康水平的影响
选取8只健康状态接近,无疾病史的绝育英短猫,年龄在6年-8年之间,按照公母各半分成两组,CON组每天饲喂H牌猫粮,NMN组每天饲喂H牌猫粮的基础上,饲喂一颗含NMN的鱼油,饲养周期2个月。试验前后分别检测猫粮的消化率、试验后的毛发质量(等级1-5分评分)、平均日采食量、试验前后体重。
表4. 饲养试验结果
组别 | 平均初体重(kg) | 平均末体重(kg) | 毛发质量 | 试验前消化率 | 试验后消化率 |
CON组 | 5.22 | 5.24 | 3.3 | 82.1% | 83.2% |
NMN组 | 5.14 | 5.21 | 4.1 | 81.6% | 85.2% |
试验结果如下,如图7所示,NMN组的平均日采食量随着饲养周期的增加而呈上升趋势,稳定在55-56克之间,表4的结果显示,消化率和平均体重也具有略微提升,毛发质量也具有一定的改善,说明饲喂含NMN抗衰老保健品能在一定程度上改善猫的体质。
上述试验结果和实施例是对本发明的具体描述,但是本发明不仅局限于上述的具体实施方式,上述试验结果仅仅是部分配方的配比和产品形态,并不是限制在这些配比和形态当中,同样的配比可以做成不同形态(冻干、粉剂、胶囊、液体)的产品。对于所属领域的普通技术人员来说,在上述说明的基础上还可以做出其它不同形式的变化或变动,本领域的普通技术人员能从本发明公开的内容直接导出或联想到的所有变形,均应认为是本发明的保护范围。本发明的保护范围由所附权利要求及其任何等同物给出。
Claims (5)
1.一种NMN的制备方法,其特征在于:步骤如下:
1)微生物培养
含NMN短双岐杆菌培养基条件为:MRS培养,进行催化NMN的表达;所述的MRS含1%蛋白胨,2%葡萄糖,0.1%吐温80,0.2%K2HPO4,0.5%乙酸钠,0.2% 氢二铵,0.02%MgSO4·7H2O,0.005% MnSO4·4H2O,0.1%微量金属溶解液和0.0076%的尿嘧啶,外源添加催化酶烟酰胺磷酸核糖转移酶(nicotinamide phosphoribosyltransferase);
2)NMN培养滤液获取
含NMN的短双岐杆菌用转速2200g进行离心,分别收集每管细胞的上清液,将细胞进重悬浮,再利用超声细胞破碎器在冰浴上进行超声裂解,每次30秒,循环3次,超声进一步裂解之后再行超滤最终得到NMN料液;
3)NMN料液萃取
将含NMN料液与相同体积的质量百分比浓度4% 的NaHCO3混合,用于Bond Elut PBA树脂固相萃取;萃取液用3ml 2%的NaHCO3洗涤后,再用3ml 2%的甲酸进行洗脱,得到β-NMN萃取液;
4)NMN原料制备
用离子交换法进行对NMN萃取液进行除盐处理,然后用醇提水沉法进行脱色处理,脱完色后用蒸发溶剂法进行NMN液体的结晶,结晶样品加水溶解,用转速2200g进行离心过滤,最后对样品进行干燥后得到NMN原料。
2.根据权利要求1所述的制备方法,其特征在于:所述的短双歧杆菌的编号为bifidobacterium breve K,双歧杆菌属,先准备短双岐杆菌感受态细胞,然后导入含有NMN活性序列的质粒到感受态的短双岐杆菌得到NMN短双岐杆菌。
3.根据权利要求1所述的制备方法,其特征在于:所述的烟酰胺磷酸核糖转移酶为外源酶,添加量8g/L。
4.一种含NMN的犬猫抗衰老保健品配方,其特征在于:按质量份,包括60-85份鱼油、1-10份β-NMN、0.05-0.2份白藜芦醇、5-20份牛磺酸和1-15份卵磷脂;所述的β-NMN根据权利要求1所述的制备方法制备得到。
5.根据权利要求4所述的含NMN的犬猫抗衰老保健品配方,其特征在于:包括冻干、粉剂、胶囊或者液体的形态。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111110078.5A CN113832204A (zh) | 2021-09-22 | 2021-09-22 | Nmn的制备方法及含nmn的犬猫抗衰老保健品配方 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111110078.5A CN113832204A (zh) | 2021-09-22 | 2021-09-22 | Nmn的制备方法及含nmn的犬猫抗衰老保健品配方 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113832204A true CN113832204A (zh) | 2021-12-24 |
Family
ID=78968954
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111110078.5A Pending CN113832204A (zh) | 2021-09-22 | 2021-09-22 | Nmn的制备方法及含nmn的犬猫抗衰老保健品配方 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113832204A (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115428859A (zh) * | 2022-09-14 | 2022-12-06 | 泓博元生命科技(深圳)有限公司 | 一种宠物适口性佳的nmn/维生素b族及微量元素功效组合物及其制备方法 |
CN115530289A (zh) * | 2022-09-27 | 2022-12-30 | 深圳壹零捌生物工程科技有限公司 | 一种宠物复方生命细胞营养素 |
CN116114796A (zh) * | 2022-10-31 | 2023-05-16 | 山东省海洋资源与环境研究院(山东省海洋环境监测中心、山东省水产品质量检验中心) | 一种应激保护剂及其制备方法与应用 |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016158212A1 (ja) * | 2015-03-31 | 2016-10-06 | 新興和製薬株式会社 | レスベラトロールとニコチンアミドモノヌクレオチドを含む食品組成物 |
CN111166760A (zh) * | 2019-12-17 | 2020-05-19 | 浙江安赛新材料科技有限公司 | β-烟酰胺单核苷酸或其前体的组合物及制备方法、应用 |
US20200332332A1 (en) * | 2017-09-29 | 2020-10-22 | Mitsubishi Chemical Corporation | Method for Producing Nicotinamide Mononucleotide and Transformant Used in Said Method |
CN111996208A (zh) * | 2020-05-25 | 2020-11-27 | 南宁邦尔克生物技术有限责任公司 | 一种利用重组枯草芽孢杆菌生产烟酰胺单核苷酸的方法 |
CN112089775A (zh) * | 2020-10-30 | 2020-12-18 | 成都及禾生物科技有限公司 | 一种nmn有益菌健康组合物及其制备方法和应用 |
US20210077514A1 (en) * | 2019-09-16 | 2021-03-18 | Gautam Umesh Vora | Nutraceutical Composition for Improving Overall Health |
CN113016957A (zh) * | 2021-04-30 | 2021-06-25 | 云南爱尔康生物技术有限公司 | 一种含虾青素和nmn的宠物食品添加剂及其制作方法 |
CN113208117A (zh) * | 2021-06-03 | 2021-08-06 | 泰州职业技术学院 | 一种含有nmn和牛磺酸的组合物及其应用 |
US20220056458A1 (en) * | 2018-12-18 | 2022-02-24 | Teijin Limited | Genetically modified microorganism and method both for producing nicotinamide derivative, and vector for use in same |
-
2021
- 2021-09-22 CN CN202111110078.5A patent/CN113832204A/zh active Pending
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016158212A1 (ja) * | 2015-03-31 | 2016-10-06 | 新興和製薬株式会社 | レスベラトロールとニコチンアミドモノヌクレオチドを含む食品組成物 |
US20200332332A1 (en) * | 2017-09-29 | 2020-10-22 | Mitsubishi Chemical Corporation | Method for Producing Nicotinamide Mononucleotide and Transformant Used in Said Method |
US20220056458A1 (en) * | 2018-12-18 | 2022-02-24 | Teijin Limited | Genetically modified microorganism and method both for producing nicotinamide derivative, and vector for use in same |
US20210077514A1 (en) * | 2019-09-16 | 2021-03-18 | Gautam Umesh Vora | Nutraceutical Composition for Improving Overall Health |
CN111166760A (zh) * | 2019-12-17 | 2020-05-19 | 浙江安赛新材料科技有限公司 | β-烟酰胺单核苷酸或其前体的组合物及制备方法、应用 |
CN111996208A (zh) * | 2020-05-25 | 2020-11-27 | 南宁邦尔克生物技术有限责任公司 | 一种利用重组枯草芽孢杆菌生产烟酰胺单核苷酸的方法 |
CN112089775A (zh) * | 2020-10-30 | 2020-12-18 | 成都及禾生物科技有限公司 | 一种nmn有益菌健康组合物及其制备方法和应用 |
CN113016957A (zh) * | 2021-04-30 | 2021-06-25 | 云南爱尔康生物技术有限公司 | 一种含虾青素和nmn的宠物食品添加剂及其制作方法 |
CN113208117A (zh) * | 2021-06-03 | 2021-08-06 | 泰州职业技术学院 | 一种含有nmn和牛磺酸的组合物及其应用 |
Non-Patent Citations (3)
Title |
---|
SHINICHIRO SHOJI等: "Metabolic design for selective production of nicotinamide mononucleotide from glucose and nicotinamide", 《METABOLIC ENGINEERING》, vol. 65 * |
ZHONGSHI HUANG等: "Systematic Engineering of Escherichia coli for Efficient Production of Nicotinamide Mononucleotide From Nicotinamide", 《ACS SYNTHETIC BIOLOGY》, vol. 11, no. 9, pages 2979 * |
任丽梅等: "β-烟酰胺单核苷酸功能与合成研究进展", 《生物资源》, vol. 43, no. 2, pages 127 - 132 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115428859A (zh) * | 2022-09-14 | 2022-12-06 | 泓博元生命科技(深圳)有限公司 | 一种宠物适口性佳的nmn/维生素b族及微量元素功效组合物及其制备方法 |
CN115530289A (zh) * | 2022-09-27 | 2022-12-30 | 深圳壹零捌生物工程科技有限公司 | 一种宠物复方生命细胞营养素 |
CN116114796A (zh) * | 2022-10-31 | 2023-05-16 | 山东省海洋资源与环境研究院(山东省海洋环境监测中心、山东省水产品质量检验中心) | 一种应激保护剂及其制备方法与应用 |
CN116114796B (zh) * | 2022-10-31 | 2024-04-02 | 山东省海洋资源与环境研究院(山东省海洋环境监测中心、山东省水产品质量检验中心) | 一种应激保护剂及其制备方法与应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN113832204A (zh) | Nmn的制备方法及含nmn的犬猫抗衰老保健品配方 | |
CN102823772B (zh) | 一种抗猪热应激的富硒复合菌饲料添加剂及其应用 | |
CN100362091C (zh) | 硒酵母产物,制备硒酵母产物的方法以及所述产物在制备食品、膳食补充品或药品中的用途 | |
CN109497257A (zh) | 一种促进瘤胃发酵和提高免疫力的肉牛用发酵饲料及其制备方法 | |
Zain et al. | Effect of yeast (Saccharomyces cerevisiae) on fermentability, microbial population and digestibility of low quality roughage in vitro | |
CN101999523B (zh) | 一种抗热应激和促生长的饲料添加剂及其制备方法 | |
CN101508961A (zh) | 一种富铜酵母的制备方法 | |
Xiong et al. | Dietary stevia residue extract supplementation improves the performance and antioxidative capacity of growing–finishing pigs | |
Fayed et al. | Effect of feeding olive tree pruning by-products on sheep performance in Sinai | |
Du et al. | Effects of diets with various levels of forage rape (Brassi ca napus) on growth performance, carcass traits, meat quality and rumen microbiota of Hu lambs | |
Oeztuerk et al. | Effects of hydrolysed yeasts on ruminal fermentation in the rumen simulation technique (Rusitec) | |
KR101721900B1 (ko) | 반추동물의 메탄 저감용 조성물 및 이를 포함하는 사료 조성물 | |
BR112019012805B1 (pt) | Composição para a nutrição de um mamífero não-humano, vasilha de alimentação para um mamífero não-humano, e, uso da composição | |
Liu et al. | Non-genetic factors affecting the meat quality and flavor of Inner Mongolian lambs: A review | |
CN105941914A (zh) | 一种育肥猪饲料 | |
Cheng et al. | Effect of grape pomace supplement on growth performance, gastrointestinal microbiota, and methane production in Tan lambs | |
Mista et al. | The effect of Linola and W92/72 transgenic flax seeds on the rabbit caecal fermentation-in vitro study | |
Iwańska et al. | The effect of Saccharomyces cerevisiae 1026 used alone or with vitamin-mineral premix on biochemical parameters of blood and milk in dairy cows | |
Shihab et al. | Effect of Saccharomyces cerevisiae on the characteristics of rumen fluid and some of blood variables in adult Awassi lamls | |
KR100401486B1 (ko) | 미역부산물의 급여에 의한 고품질 한우육의 생산 방법 | |
Lu et al. | Effects of sources and levels of dietary supplementary manganese on growing yak’s in vitro rumen fermentation | |
Nasser | Influence of dietary cobalt on performance, nutrient digestibility and rumen activity in lambs | |
Ariyanto et al. | Effect of Water Hyacinth Leaf Flour (Eichhornia crassipes) Fermented by Aspergillus niger on the Growth, Survival Rate and Blood Profile of Sangkuriang Catfish (Clarias gariepinus) | |
Ariyanto et al. | Effect of water hyacinth leaf flour (Eichhornia crassipes) fermented by Aspergillus niger in the commercial pellet on the growth, survival rate and blood profile of sangkuriang catfish (Clarias gariepinus). | |
Al-ghazali | Effect of Treating Date Peels with Different Levels of Yeast (Saccharomyces cerevisiae) on Some Fermentations of Rumen Fluid in Vitro |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20211224 |